Rabbit Anti-Human CYP3A4 (a.a. 11-120) Polyclonal antibody

In order to rapidly identify the phenotypic profile and possible off-target liability effects of novel synthesized thyromimetics for selection of lead compounds for further optimization studies, we performed in vitro screening on a new small library of synthetic thyromimetics. A comprehensive panel of early toxicity assays comprising cytotoxicity on 4 different cell lines ( osteosarcoma, U2OS; lung fibroblast, hTERT; human breast adenocarcinoma, MCF7; human embryonic kidney, HEK293), hERG liability, cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoforms), and off-target liability against selected proteins (Aurora B kinase and phosphodiesterase PDE4C1) and epigenetic enzymes (HDAC4, HDAC6, HDAC8, HDAC9 & SIRT7). All the compounds were screened at 10 mu M in at least triplicate using well-established in vitro assays with readouts in luminescence or fluorescence polarization mode. The raw data were processed using Microsoft Excel and the Z' for each assay was calculated (acceptable Z' >0.40). The processed and normalized data were organized in tables and visualized using spider plots. The results which are reported in the present manuscript can be used in prediction studies of early toxicity and off-target liabilities of other thyromimetics using in silico methods. The data reported herein support our research article entitled "Design, synthesis and biological evaluation of novel TR beta selective agonists sustained by ADME-Toxicity analysis" by Runfola M., Sestito S., et al. [1] (c) 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The aim of this study was to demonstrate an interaction between a synthetic glucocorticoid and a non-nucleoside reverse transcriptase inhibitor (NNRTI), i.e. budesonide and rilpivirine. This evaluation was done in vitro using human liver microsomes. The authors were involved in the case of a 29-year-old woman presenting an latrogenic Cushing's syndrome following the implementation of a budesonide treatment. The patient was also treated with rilpivirine for HIV virus infection. Drugs were administered at therapeutic doses. The clinicians supposed that the latrogenic Cushing's syndrome would be the result of a budesonide accumulation in the body. As a first step, to establish the chromatographic behavior (retention time, transition) of the two main metabolites of budesonide (16 alpha-OH-prednisolone and 6 beta-OH-budesonide), a healthy volunteer took 2.2 mg of budesonide, and his urine was collected for 24 h. An original method by UHPLC/MS-MS was used. Then, the possible interaction between rilpivirine and budesonide was evaluated with human liver microsomes (HLMs). During the simultaneous incubation, a decrease in production of the two budesonide's metabolites and an accumulation of the parent molecule were observed. With a rilpivirine concentration at 10 mg/L, an increase in the budesonide response of 41.4% was noticed while the metabolites' production decreased. More specifically, the response for 16 alpha-OH-prednisolone decreased of 69.0% and the response for the 6 beta-OH-budesonide decreased of 59.2%. It was concluded that rilpivirine is a probable inhibitor of the cytochrome CYP3A4, and has an effect on the budesonide metabolization. This observation appears to be the first study proving the in vitro interaction between these two molecules. (C) 2019 Published by Elsevier Masson SAS on behalf of Societe Francaise de Toxicologie Analytique.